{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T23:00:15Z","timestamp":1790290815978,"version":"4.1.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,9,29]],"date-time":"2021-09-29T00:00:00Z","timestamp":1632873600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,9,29]],"date-time":"2021-09-29T00:00:00Z","timestamp":1632873600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Pierre Fabre Ib\u00e9rica S.A."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>In a subset analysis of data from a 6-month, multicenter, non-interventional study, we compared change in symptoms and quality of life (QoL), and treatment tolerability, in men with moderate to severe lower urinary tract symptoms associated with benign prostatic hyperplasia (LUTS\/BPH) receiving tamsulosin (TAM, 0.4\u00a0mg\/day) or the hexanic extract of <jats:italic>Serenoa repens<\/jats:italic> (HESr, 320\u00a0mg\/day) as monotherapy. Symptoms and QoL were assessed using the IPSS and BII questionnaires, respectively. Patients in the treatment groups were matched using two statistical approaches (iterative and propensity score matching). Within the iterative matching approach, data was available from a total of 737 patients (353 TAM, 384 HESr). After 6\u00a0months, IPSS scores improved by a mean (SD) of 5.0 (4.3) points in the TAM group and 4.5 (4.7) points in the HESr group (<jats:italic>p<\/jats:italic>\u2009=\u20090.117, not significant). Improvements in QoL were equivalent in the two groups. TAM patients reported significantly more adverse effects than HESr patients (14.7% vs 2.1%; <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001), particularly ejaculation dysfunction and orthostatic hypotension. These results show that HESr is a valid treatment option for men with moderate\/severe LUTS\/BPH; improvements in urinary symptoms and QoL were similar to those observed for tamsulosin, but with considerably fewer adverse effects.<\/jats:p>","DOI":"10.1038\/s41598-021-98586-5","type":"journal-article","created":{"date-parts":[[2021,9,29]],"date-time":"2021-09-29T10:25:07Z","timestamp":1632911107000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Efficacy and tolerability of the hexanic extract of Serenoa repens compared to tamsulosin in moderate-severe LUTS-BPH patients"],"prefix":"10.1038","volume":"11","author":[{"given":"Antonio","family":"Alcaraz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfredo","family":"Rodr\u00edguez-Antol\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joaqu\u00edn","family":"Carballido-Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Castro-D\u00edaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9","family":"Medina-Polo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jes\u00fas M.","family":"Fern\u00e1ndez-G\u00f3mez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Ficarra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan","family":"Palou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Ponce de Le\u00f3n Roca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier C.","family":"Angulo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Esteban-Fuertes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 M.","family":"C\u00f3zar-Olmo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noem\u00ed","family":"P\u00e9rez-Le\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 M.","family":"Molero-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Fern\u00e1ndez-Pro Ledesma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco J.","family":"Brenes-Berm\u00fadez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9","family":"Manasanch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,9,29]]},"reference":[{"key":"98586_CR1","unstructured":"Gravas, S. et al. EAU guidelines on management of non-neurogenic male LUTS including benign prostatic obstruction. Available online: https:\/\/uroweb.org\/wp-content\/uploads\/EAU-Guidelines-on-Non-Neurogenic-Male-LUTS-incl.-BPO-2020.pdf (2020) (accessed on 29 March 2021)."},{"key":"98586_CR2","unstructured":"Ng, M., Baradhi, K.M. Benign prostatic hyperplasia. [Updated 2020 Aug 10]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing, Jan. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK558920\/ (2020). https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK558920\/"},{"issue":"Suppl 9","key":"98586_CR3","first-page":"S3","volume":"7","author":"CG Roehrborn","year":"2005","unstructured":"Roehrborn, C. G. Benign prostatic hyperplasia: an overview. Rev. Urol. 7(Suppl 9), S3\u2013S14 (2005).","journal-title":"Rev. Urol."},{"key":"98586_CR4","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1111\/bju.12745","volume":"115","author":"M Speakman","year":"2015","unstructured":"Speakman, M., Kirby, R., Doyle, S. & Ioannou, C. Burden of male lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH) - focus on the UK. BJU Int. 115, 508\u2013519 (2015).","journal-title":"BJU Int."},{"key":"98586_CR5","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1016\/S0022-5347(01)65075-4","volume":"157","author":"TJ Peters","year":"1997","unstructured":"Peters, T. J. et al. The International Continence Society \u201cBenign Prostatic Hyperplasia\u201d Study: the bothersomeness of urinary symptoms. J. Urol. 157, 885\u2013889 (1997).","journal-title":"J. Urol."},{"issue":"Suppl 3","key":"98586_CR6","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1111\/j.1464-410X.2009.08371.x","volume":"103","author":"KS Coyne","year":"2009","unstructured":"Coyne, K. S. et al. The burden of lower urinary tract symptoms: evaluating the effect of LUTS on health-related quality of life, anxiety and depression: EpiLUTS. BJU Int. 103(Suppl 3), 4\u201311 (2009).","journal-title":"BJU Int."},{"key":"98586_CR7","doi-asserted-by":"publisher","first-page":"132","DOI":"10.5213\/inj.2012.16.3.132","volume":"16","author":"HJ Song","year":"2012","unstructured":"Song, H. J. et al. Impact of lower urinary tract symptoms and depression on health-related quality of life in older adults. Int. Neurourol. J. 16, 132\u2013138 (2012).","journal-title":"Int. Neurourol. J."},{"key":"98586_CR8","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/S0302-2838(02)00041-6","volume":"41","author":"D Mitropoulos","year":"2002","unstructured":"Mitropoulos, D. et al. Symptomatic benign prostate hyperplasia: impact on partners\u2019 quality of life. Eur. Urol. 41, 240\u2013245 (2002).","journal-title":"Eur. Urol."},{"key":"98586_CR9","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1111\/jsm.12525","volume":"11","author":"M Gacci","year":"2014","unstructured":"Gacci, M. et al. Impact of medical treatments for male lower urinary tract symptoms due to benign prostatic hyperplasia on ejaculatory function: A systematic review and meta-analysis. J. Sex. Med. 11, 1554\u20131566 (2014).","journal-title":"J. Sex. Med."},{"key":"98586_CR10","doi-asserted-by":"crossref","unstructured":"Vela-Navarrete, R., Garcia Cardoso, J. V., Barat, A., Manzarbeitia, F. & L\u00f3pez Farr\u00e9, A. BPH and inflammation: pharmacological effects of Permixon on histological and molecular inflammatory markers. Results of a double-blind pilot clinical assay.\u00a0Eur. Urol.\u00a044, 549\u2013555 (2003).","DOI":"10.1016\/S0302-2838(03)00368-3"},{"key":"98586_CR11","doi-asserted-by":"publisher","first-page":"E301","DOI":"10.1111\/j.1464-410X.2012.11144.x","volume":"110","author":"A Latil","year":"2012","unstructured":"Latil, A. et al. Hexanic lipidosterolic extract of Serenoa repens inhibits the expression of two key inflammatory mediators, MCP-1\/CCL2 and VCAM-1, in vitro. BJU Int. 110, E301\u2013E307 (2012).","journal-title":"BJU Int."},{"key":"98586_CR12","doi-asserted-by":"publisher","first-page":"14301","DOI":"10.3390\/ijms140714301","volume":"14","author":"N Sirab","year":"2013","unstructured":"Sirab, N. et al. Lipidosterolic extract of serenoa repens modulates the expression of inflammation related-genes in benign prostatic hyperplasia epithelial and stromal cells. Int. J. Mol. Sci. 14, 14301\u201314320 (2013).","journal-title":"Int. J. Mol. Sci."},{"key":"98586_CR13","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1007\/s00345-018-2409-1","volume":"37","author":"S Gravas","year":"2019","unstructured":"Gravas, S. et al. The effect of hexanic extract of Serenoa repens on prostatic inflammation: results from a randomized biopsy study. World J. Urol. 37, 539\u2013544 (2019).","journal-title":"World J. Urol."},{"key":"98586_CR14","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1159\/000161128","volume":"82","author":"F Scaglione","year":"2008","unstructured":"Scaglione, F., Lucini, V., Pannacci, M., Dugnani, S. & Leone, C. Comparison of the potency of different brands of Serenoa repens extract on 5alpha-reductase types I and II in prostatic co-cultured epithelial and fibroblast cells. Pharmacology 82, 270\u2013275 (2008).","journal-title":"Pharmacology"},{"key":"98586_CR15","first-page":"569","volume":"16","author":"F Scaglione","year":"2012","unstructured":"Scaglione, F., Lucini, V., Pannacci, M., Dugnani, S. & Leone, C. Comparison of the potency of 10 different brands of Serenoa repens extracts. Eur. Rev. Med. Pharmacol. Sci. 16, 569\u2013574 (2012).","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"98586_CR16","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1002\/(SICI)1097-0045(19990901)40:4<232::AID-PROS4>3.0.CO;2-0","volume":"40","author":"CW Bayne","year":"1999","unstructured":"Bayne, C. W., Donnelly, F., Ross, M. & Habib, F. K. Serenoa repens (Permixon): A 5alpha-reductase types I and II inhibitor-new evidence in a coculture model of BPH. Prostate 40, 232\u2013241 (1999).","journal-title":"Prostate"},{"key":"98586_CR17","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1002\/(SICI)1097-0045(19981001)37:2<77::AID-PROS3>3.0.CO;2-I","volume":"37","author":"F Di Silverio","year":"1998","unstructured":"Di Silverio, F. et al. Effects of long-term treatment with Serenoa repens (Permixon) on the concentrations and regional distribution of androgens and epidermal growth factor in benign prostatic hyperplasia. Prostate 37, 77\u201383 (1998).","journal-title":"Prostate"},{"key":"98586_CR18","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1007\/s11255-015-1206-7","volume":"48","author":"A Alcaraz","year":"2016","unstructured":"Alcaraz, A. et al. Quality of life in patients with lower urinary tract symptoms associated with BPH: Change over time in real-life practice according to treatment\u2013the QUALIPROST study. Int. Urol. Nephrol. 48, 645\u2013656 (2016).","journal-title":"Int. Urol. Nephrol."},{"key":"98586_CR19","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1136\/bmj.39335.541782.AD","volume":"335","author":"E von Elm","year":"2007","unstructured":"von Elm, E. et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. BMJ 335, 806\u2013808 (2007).","journal-title":"BMJ"},{"key":"98586_CR20","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1038\/sj.pcan.4500746","volume":"7","author":"FK Habib","year":"2004","unstructured":"Habib, F. K. & Wyllie, M. G. Not all brands are created equal: a comparison of selected components of different brands of Serenoa repens extract. Prostate Cancer Prostatic Dis. 7, 195\u2013200 (2004).","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"98586_CR21","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1016\/S0022-5347(01)66780-6","volume":"154","author":"MJ Barry","year":"1995","unstructured":"Barry, M. J. et al. Benign prostatic hyperplasia specific health status measures in clinical research: how much change in the American Urological Association symptom index and the benign prostatic hyperplasia impact index is perceptible to patients?. J. Urol. 154, 1770\u20131774 (1995).","journal-title":"J. Urol."},{"issue":"4 Suppl","key":"98586_CR22","first-page":"AS145","volume":"33","author":"MJ Barry","year":"1995","unstructured":"Barry, M. J. et al. Measuring disease-specific health status in men with benign prostatic hyperplasia. Measurement Committee of The American Urological Association. Med. Care 33(4 Suppl), AS145\u2013AS155 (1995).","journal-title":"Med. Care"},{"key":"98586_CR23","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/S0210-4806(08)73818-X","volume":"32","author":"J CarballidoRodr\u00edguez","year":"2008","unstructured":"CarballidoRodr\u00edguez, J. et al. Validation of the Spanish version of the Benign Prostatic Hyperplasia Impact Index Questionnaire. \u201cValidart Study\u201d. Actas Urol. Esp. 32, 230\u2013239 (2008).","journal-title":"Actas Urol. Esp."},{"issue":"7972","key":"98586_CR24","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1016\/S0140-6736(76)91737-2","volume":"1","author":"RB Haynes","year":"1976","unstructured":"Haynes, R. B. et al. Improvement of medication compliance in uncontrolled hypertension. Lancet 1(7972), 1265\u20131268 (1976).","journal-title":"Lancet"},{"key":"98586_CR25","unstructured":"R Core Team. R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing. Vienna, Austria. https:\/\/www.R-project.org (2018)."},{"key":"98586_CR26","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1002\/pds.4297","volume":"26","author":"ML Berger","year":"2017","unstructured":"Berger, M. L. et al. Good practices for real-world data studies of treatment and\/or comparative effectiveness: Recommendations from the joint ISPOR-ISPE Special Task Force on real-world evidence in health care decision making. Pharmacoepidemiol. Drug Saf. 26, 1033\u20131039 (2017).","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"98586_CR27","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/S0302-2838(02)00066-0","volume":"41","author":"F Debruyne","year":"2002","unstructured":"Debruyne, F. et al. Comparison of a phytotherapeutic agent (Permixon) with an alpha-blocker (Tamsulosin) in the treatment of benign prostatic hyperplasia: a 1-year randomized international study. Eur. Urol. 41, 497\u2013506 (2002).","journal-title":"Eur. Urol."},{"issue":"16","key":"98586_CR28","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.1002\/pros.23059","volume":"75","author":"A Latil","year":"2015","unstructured":"Latil, A., P\u00e9trissans, M. T., Rouquet, J., Robert, G. & de la Taille, A. Effects of hexanic extract of Serenoa repens (Permixon 160 mg) on inflammation biomarkers in the treatment of lower urinary tract symptoms related to benign prostatic hyperplasia. Prostate 75(16), 1857\u20131867 (2015).","journal-title":"Prostate"},{"key":"98586_CR29","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/1471-2490-14-63","volume":"14","author":"C De Monte","year":"2014","unstructured":"De Monte, C. et al. Modern extraction techniques and their impact on the pharmacological profile of Serenoa repens extracts for the treatment of lower urinary tract symptoms. BMC Urol. 14, 63 (2014).","journal-title":"BMC Urol."},{"key":"98586_CR30","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1056\/NEJMoa053085","volume":"354","author":"S Bent","year":"2006","unstructured":"Bent, S. et al. Saw palmetto for benign prostatic hyperplasia. NEJM 354, 557\u2013566 (2006).","journal-title":"NEJM"},{"key":"98586_CR31","unstructured":"European Medicines Agency. Assessment Report on Serenoa repens (W. Bartram) Small, fructus. Final. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Herbal_-_HMPC_assessment_report\/2016\/03\/WC500203896.pdf. Published 24 November 2015 (accessed on 5 February 2021)."},{"key":"98586_CR32","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1111\/bju.14362","volume":"122","author":"R Vela-Navarrete","year":"2018","unstructured":"Vela-Navarrete, R. et al. Efficacy and safety of a hexanic extract of Serenoa repens (Permixon\u00ae) for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia (LUTS\/BPH): Systematic review and meta-analysis of randomized controlled trials and observational studies. BJU Int. 122, 1049\u20131065 (2018).","journal-title":"BJU Int."},{"key":"98586_CR33","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/j.euf.2016.04.002","volume":"2","author":"G Novara","year":"2016","unstructured":"Novara, G. et al. Efficacy and safety of hexanic lipidosterolic extract of Serenoa repens (Permixon) in the treatment of lower urinary tract symptoms due to benign prostatic hyperplasia: systematic review and meta-analysis of randomized controlled trials. Eur. Urol. Focus. 2, 553\u2013561 (2016).","journal-title":"Eur. Urol. Focus."},{"key":"98586_CR34","unstructured":"Gravas, S. et al. EAU guidelines on management of non-neurogenic male LUTS incl. benign prostatic obstruction. https:\/\/uroweb.org\/wp-content\/uploads\/EAU-Guidelines-on-Management-of-Non-Neurogenic-Male-LUTS-2021.pdf (2021) (accessed on 9 April 2021)."},{"key":"98586_CR35","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1111\/j.1464-410X.2009.08196.x","volume":"103","author":"J Barkin","year":"2009","unstructured":"Barkin, J. et al. Effect of dutasteride, tamsulosin and the combination on patient-reported quality of life and treatment satisfaction in men with moderate-to-severe benign prostatic hyperplasia: 2-year data from the CombAT trial. BJU Int. 103, 919\u2013926 (2009).","journal-title":"BJU Int."},{"key":"98586_CR36","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1016\/j.eururo.2004.01.015","volume":"45","author":"F Debruyne","year":"2004","unstructured":"Debruyne, F. et al. Evaluation of the clinical benefit of permixon and tamsulosin in severe BPH patients-PERMAL study subset analysis. Eur. Urol. 45, 773\u2013780 (2004).","journal-title":"Eur. Urol."},{"issue":"1","key":"98586_CR37","doi-asserted-by":"publisher","first-page":"13223","DOI":"10.1038\/s41598-018-31617-w","volume":"8","author":"HW Moon","year":"2018","unstructured":"Moon, H. W. et al. Prescription pattern of alpha-blockers for management of lower urinary tract symptoms\/benign prostatic hyperplasia. Sci. Rep. 8(1), 13223 (2018).","journal-title":"Sci. Rep."},{"key":"98586_CR38","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1093\/ageing\/afv077","volume":"44","author":"M Oelke","year":"2015","unstructured":"Oelke, M. et al. Appropriateness of oral drugs for long-term treatment of lower urinary tract symptoms in older persons: results of a systematic literature review and international consensus validation process (LUTS-FORTA 2014). Age Ageing 44, 745\u2013755 (2015).","journal-title":"Age Ageing"},{"key":"98586_CR39","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1002\/pds.4361","volume":"27","author":"Y Duan","year":"2018","unstructured":"Duan, Y., Grady, J. J., Albertsen, P. C. & Helen Wu, Z. Tamsulosin and the risk of dementia in older men with benign prostatic hyperplasia. Pharmacoepidemiol. Drug Saf. 27, 340\u2013348 (2018).","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"98586_CR40","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1016\/j.juro.2010.12.080","volume":"185","author":"SA Kaplan","year":"2011","unstructured":"Kaplan, S. A. Re: The Effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT Study. J. Urol. 185, 1384\u20131385 (2011).","journal-title":"J. Urol."},{"key":"98586_CR41","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1007\/s11934-012-0278-5","volume":"13","author":"JR Bell","year":"2012","unstructured":"Bell, J. R. & Laborde, E. Update on the sexual impact of treatment for benign prostatic hyperplasia. Curr, Urol, Rep. 13, 433\u2013440 (2012).","journal-title":"Curr, Urol, Rep."},{"key":"98586_CR42","doi-asserted-by":"publisher","first-page":"295","DOI":"10.21037\/tau.2017.03.57","volume":"6","author":"J Gandhi","year":"2017","unstructured":"Gandhi, J. et al. The impact and management of sexual dysfunction secondary to pharmacological therapy of benign prostatic hyperplasia. Transl. Androl. Urol. 6, 295\u2013304 (2017).","journal-title":"Transl. Androl. Urol."},{"issue":"4 Pt 1","key":"98586_CR43","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1016\/j.juro.2006.06.004","volume":"176","author":"WJ Hellstrom","year":"2006","unstructured":"Hellstrom, W. J. & Sikka, S. C. Effects of acute treatment with tamsulosin versus alfuzosin on ejaculatory function in normal volunteers. J. Urol. 176(4 Pt 1), 1529\u20131533 (2006).","journal-title":"J. Urol."},{"key":"98586_CR44","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.eururo.2009.09.035","volume":"57","author":"CG Roehrborn","year":"2010","unstructured":"Roehrborn, C. G. et al. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. Eur. Urol. 57, 123\u2013131 (2010).","journal-title":"Eur. Urol."},{"key":"98586_CR45","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/BF02853175","volume":"19","author":"YA Pytel","year":"2002","unstructured":"Pytel, Y. A. et al. Long-term clinical and biologic effects of the lipidosterolic extract of Serenoa repens in patients with symptomatic benign prostatic hyperplasia. Adv. Ther. 19, 297\u2013306 (2002).","journal-title":"Adv. Ther."},{"key":"98586_CR46","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.jep.2013.12.030","volume":"152","author":"T Chua","year":"2014","unstructured":"Chua, T., Eise, N. T., Simpson, J. S. & Ventura, S. Pharmacological characterization and chemical fractionation of a liposterolic extract of saw palmetto (Serenoa repens): Effects on rat prostate contractility. J. Ethnopharmacol. 152, 283\u2013291 (2014).","journal-title":"J. Ethnopharmacol."},{"key":"98586_CR47","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/0306-3623(95)00094-1","volume":"27","author":"M Gutierrez","year":"1996","unstructured":"Gutierrez, M., Garc\u00eda de Boto, M. J., Cantabrana, B. & Hidalgo, A. Mechanisms involved in the spasmolytic effect of extracts from Sabal serrulata fruit on smooth muscle. Gen. Pharmacol. 27, 171\u2013176 (1996).","journal-title":"Gen. Pharmacol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-98586-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-98586-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-98586-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T16:16:50Z","timestamp":1670084210000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-98586-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,29]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["98586"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-98586-5","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,29]]},"assertion":[{"value":"27 May 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 August 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"J.M. is a medical advisor with Pierre Fabre Ib\u00e9rica S.A., a company that commercializes an extract of <i>Serenoa repens<\/i>. The other authors declare no potential conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"19401"}}